ConductScience.org, home

Paper3122880

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

Kontoghiorghes GJ and 6 others. Br Med J (Clin Res Ed), 1987. Cited by 192 papers, by iCite.

Cite this record

ConductScience Library. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Papers, record 3122880. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3122880

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
PubMed
Journal
Br Med J (Clin Res Ed)
PubMed
Year
1987
PubMed
Publication types
Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
192
iCite
Relative citation ratio, by iCite
7.01
iCite
Revised in PubMed
2023-11-20
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kontoghiorghes GJG J
2Aldouri MAM A
3Hoffbrand AVA V
4Barr JJ
5Wonke BB
6Kourouclaris TT
7Sheppard LL

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
IronMajor topic
Iron Chelating AgentsMajor topic
PyridonesMajor topic
ThalassemiaMajor topic
Administration, Oral
Adolescent
Adult
Aged
Ascorbic Acid
Clinical Trials as Topic
Deferiprone
Deferoxamine
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Neural Tube Defects

Source PubMed

Download CSV of topics

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13954731Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators.Biochem J1986https://conductscience.org/library/papers/3954731PubMed
23964556Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.Br J Haematol1986https://conductscience.org/library/papers/3964556PubMed
33708002Iron mobilisation from lactoferrin by chelators at physiological pH.Biochim Biophys Acta1986https://conductscience.org/library/papers/3708002PubMed
43738427Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).Scand J Haematol1986https://conductscience.org/library/papers/3738427PubMed
53764334Dose response studies using desferrioxamine and orally active chelators in a mouse model.Scand J Haematol1986https://conductscience.org/library/papers/3764334PubMed
63566714Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators.Biochem J1987https://conductscience.org/library/papers/3566714PubMed
728844151,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.Lancet1987https://conductscience.org/library/papers/2884415PubMed
83435580New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.Arzneimittelforschung1987https://conductscience.org/library/papers/3435580PubMed
963749Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.Lancet1976https://conductscience.org/library/papers/63749PubMed
10882111Continuous subcutaneous administration of deferoxamine in patients with iron overload.N Engl J Med1977https://conductscience.org/library/papers/882111PubMed
11108388Rhodotorulic acid--investigation of its potential as an iron-chelating drug.J Pharmacol Exp Ther1979https://conductscience.org/library/papers/108388PubMed
12497121Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone.Br J Haematol1979https://conductscience.org/library/papers/497121PubMed
136106796Iron chelation with oral desferrioxamine.Lancet1980https://conductscience.org/library/papers/6106796PubMed
147093519Ferrioxamine excretion in iron-loaded man.Blood1982https://conductscience.org/library/papers/7093519PubMed
156135933Desferrioxamine suppositories.Lancet1983https://conductscience.org/library/papers/6135933PubMed
166227988[Iron chelation. Biological significance and medical application].Schweiz Med Wochenschr1983https://conductscience.org/library/papers/6227988PubMed
176699459Phenolic ethylenediamine derivatives: a study of orally effective iron chelators.J Lab Clin Med1984https://conductscience.org/library/papers/6699459PubMed
182858689New orally active iron chelators.Lancet1985https://conductscience.org/library/papers/2858689PubMed
193942757The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.Biochim Biophys Acta1986https://conductscience.org/library/papers/3942757PubMed
203485251Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.N Engl J Med1986https://conductscience.org/library/papers/3485251PubMed

Download CSV of references

Cited by42

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 192 citations.

PMIDTitleJournalYearIn PapersSource
42797332Insights into the Complexities of Pharmacotherapy Parameters in Artificial Intelligence Models for Drug Selection, Precision Personalised Medicine and Optimal Therapeutic Outcomes.Pharmaceutics2026https://conductscience.org/library/papers/42797332PubMed
41156522Development of Iron-Chelating/Antioxidant Nutraceuticals and Natural Products as Pharmaceuticals for Clinical Use in Diseases with Free Radical Pathologies.Nutrients2025https://conductscience.org/library/papers/41156522PubMed
38791185The Puzzle of Aspirin and Iron Deficiency: The Vital Missing Link of the Iron-Chelating Metabolites.Int J Mol Sci2024https://conductscience.org/library/papers/38791185PubMed
38515856Article review: Brazilin as potential anticancer agent.Front Pharmacol2024https://conductscience.org/library/papers/38515856PubMed
38069073Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.Int J Mol Sci2023https://conductscience.org/library/papers/38069073PubMed
37513928The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37513928PubMed
36902402Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.Int J Mol Sci2023https://conductscience.org/library/papers/36902402PubMed
36785546Serum Ferritin Levels and Other Associated Parameters with Diabetes Mellitus in Adult Patients Suffering from Beta Thalassemia Major.J Blood Med2023https://conductscience.org/library/papers/36785546PubMed
35743183Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.Int J Mol Sci2022https://conductscience.org/library/papers/35743183PubMed
35163169Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine.Int J Mol Sci2022https://conductscience.org/library/papers/35163169PubMed
33805195Is Chelation Therapy a Potential Treatment for Parkinson's Disease?Int J Mol Sci2021https://conductscience.org/library/papers/33805195PubMed
32751493Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications.Medicines (Basel)2020https://conductscience.org/library/papers/32751493PubMed
32545424Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.Cells2020https://conductscience.org/library/papers/32545424PubMed
31934321The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.Mediterr J Hematol Infect Dis2020https://conductscience.org/library/papers/31934321PubMed
31533229The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain.Pharmaceuticals (Basel)2019https://conductscience.org/library/papers/31533229PubMed
28809446Deferasirox for managing iron overload in people with thalassaemia.Cochrane Database Syst Rev2017https://conductscience.org/library/papers/28809446PubMed
27276421Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.Br J Clin Pharmacol2016https://conductscience.org/library/papers/27276421PubMed
27019793New developments and controversies in iron metabolism and iron chelation therapy.World J Methodol2016https://conductscience.org/library/papers/27019793PubMed
26056604Polymeric nanocarriers for the treatment of systemic iron overload.Mol Cell Ther2015https://conductscience.org/library/papers/26056604PubMed
25541601Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.World J Methodol2014https://conductscience.org/library/papers/25541601PubMed

See all 42 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3122880

GET https://conductscience.org/api/papers/v1/3122880/cited_by?page=2